Melatonin use reduces risk of self-harm in young people, study finds

Written By :  Dr. Kamal Kant Kohli
Published On 2023-03-29 04:00 GMT   |   Update On 2023-03-29 09:20 GMT

Sweden: Melatonin treatment in females with anxiety and depression is associated with a reduced risk of intentional self-harm, indicating that sleep interventions could be considered to reduce self-harm risk in this population, an observational study from Karolinska Institutet in Sweden has shown. The study appeared in The Journal of Child Psychology and Psychiatry.Medical sleep treatment...

Login or Register to read the full article

Sweden: Melatonin treatment in females with anxiety and depression is associated with a reduced risk of intentional self-harm, indicating that sleep interventions could be considered to reduce self-harm risk in this population, an observational study from Karolinska Institutet in Sweden has shown. The study appeared in The Journal of Child Psychology and Psychiatry.

Medical sleep treatment reduced self-harm in young people with depression and anxiety, especially in girls. 

Melatonin is a hormone that controls the sleep-wake cycle and is the most commonly prescribed drug for sleep disturbances in children and adolescents in Sweden. Melatonin use has dramatically increased in recent years, and it is available over the counter in Sweden since 2020.

“Given the established link between sleep problems, depression, and self-harm, we wanted to explore whether medical sleep treatment is associated with a lower rate of intentional self-harm in young people,” says Dr Sarah Bergen, docent at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, who led the study.

Psychiatric disorders were common

The study identified over 25,500 children and teenagers between the ages of 6 and 18 who were prescribed melatonin in Sweden. Over 87 percent had at least one psychiatric disorder, mainly attention-deficit hyperactivity disorder (ADHD), anxiety disorders, depression, or autism spectrum disorder. Self-harm was about five times more common in girls than in boys.

The researchers estimated the risks of self-harm in the same individual while on or off medication by comparing the risk in the last unmedicated month with the twelve months after melatonin treatment was initiated. By doing so, they were able to take into account background factors that may affect associations, such as genetics, sleep disorder severity, or psychiatric disorders.

The risk of self-harm increased shortly before melatonin was prescribed and decreased by about half in the months following the initiation of treatment. Risk reduction was particularly evident among adolescent girls with depression and/or anxiety disorders.

Youth mental health crisis

“There is currently a youth mental health crisis, and the risk of self-harm and suicide is high,” says Sarah Bergen. “Our findings support the hypothesis that sleep interventions may reduce self-harm in this population, especially in girls.”

As it was an observational study, it cannot establish a causal relationship between melatonin and reduced self-harm rates. To check whether the use of other medications might have affected the findings, analyses were also carried out which excluded antidepressant users. The results were similar.

“This suggests that melatonin might be responsible for the reduced self-harm rates, but we cannot rule out that the use of other psychiatric medications or psychotherapy may have influenced the findings,” says Dr Marica Leone, first author of the study and former PhD student in Sarah Bergen’s research group.

Reference:

Marica Leone, Ralf Kuja-Halkola, Tyra Lagerberg, Johan Bjureberg, Agnieszka Butwicka, Zheng Chang, Henrik Larsson, Brian M. D'Onofrio, Amy Leval, Sarah E. Bergen published: 23 March 2023 https://doi.org/10.1111/jcpp.13785.

Tags:    
Article Source : Journal of Child Psychology and Psychiatry

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News